Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy

Victorien M.T. van Verschuer¹, Marike C. Maijers², Carolien H.M. van Deurzen³, Linetta B. Koppert¹

¹Erasmus MC Cancer Institute, Department of Surgical Oncology, Rotterdam, the Netherlands; ²VUmc, Department of Plastic and Reconstructive Surgery, Amsterdam, the Netherlands; ³Erasmus MC Cancer Institute, Department of Pathology, Rotterdam, the Netherlands

Correspondence to: Victorien M.T. van Verschuer, MD. Erasmus MC Cancer Institute, Department of Surgical Oncology, Room DHD-407, P.O. Box 5201, 3008 AE Rotterdam, the Netherlands. Email: v.vanverschuer@erasmusmc.nl.

Abstract: Women with a BRCA1/2 gene mutation and others with a high breast cancer risk may opt for bilateral prophylactic mastectomy. To allow for immediate breast reconstruction the skin envelope is left in situ with or without the nipple-areola complex (NAC). Although possibly leading to a more natural aesthetic outcome than the conventional total mastectomy, so-called skin-sparing mastectomies (SSM) and nipple-sparing mastectomies (NSM) may leave some breast glandular tissue in situ. The oncological risk associated with remaining breast glandular tissue is unclear. We present a case of primary breast cancer after prophylactic mastectomy followed by a review of the literature on remaining breast glandular tissue after various mastectomy techniques and oncological safety of prophylactic mastectomies.

Keywords: Risk-reduction; skin-sparing mastectomy (SSM); nipple-sparing mastectomy (NSM); total mastectomy; primary breast cancer; breast glandular tissue; terminal duct lobular units

Submitted Dec 17, 2014. Accepted for publication Jan 29, 2015.

doi: 10.3978/j.issn.2227-684X.2015.02.01

View this article at: http://dx.doi.org/10.3978/j.issn.2227-684X.2015.02.01

Introduction

BRCA1/2 mutation carriers have a cumulative lifetime breast cancer risk of 55-85% by the age of 70 (1-5). As an alternative to surveillance, BRCA1 and BRCA2 mutation carriers and other women with a high breast cancer risk may choose to undergo bilateral prophylactic mastectomy, reducing breast cancer risks by 90-100% after 3-13 years of follow-up (6-10). The prophylactic character of the bilateral mastectomy emphasizes the importance of a natural aesthetic outcome (11), which can be achieved by various immediate autologous and implant breast reconstruction techniques. Instead of the conventional total mastectomy, to allow for an immediate breast reconstruction and to achieve a natural aesthetic outcome so-called conservative mastectomies are increasingly performed for risk reduction. In conservative mastectomies, all breast glandular tissue is removed while leaving the skin envelope and, if spared, the nipple-areola complex (NAC) in situ [skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM), respectively].

Safety of conservative mastectomies in women at high breast cancer risk is subject to an ongoing debate. The presumed oncological risk of the conservative technique lies in potential remaining breast glandular tissue with the skin flap and, if spared, with the NAC. Smaller incisions that are tailored to individual reconstruction wishes, however, may result in a technically difficult surgical approach. Therefore, the oncological safety of the conservative mastectomy remains a challenge for the oncological surgeon. We present a case of primary breast cancer developed after prophylactic conservative mastectomy. Further, we provide a review of the literature on the oncological safety of prophylactic conservative mastectomies.

Case: a 43-year-old woman with primary breast cancer in the prophylactic mastectomy scar

In 2011, a 43-year-old woman presented a lesion clinically suspicious of breast cancer. In 1982, at the age of 15, she had been successfully treated for stage IIA Hodgkin’s disease.
in her neck and mediastinum with 40 Gy mantle field radiation. After 10 years there were no signs of recurrence and she was discharged from follow-up.

In 1998, a mammography—performed because of a wish for breast reduction—revealed suspect microcalcifications in the left breast. The suspect lesion was excised by upper outer quadrantectomy. Pathological examination of the lumpectomy specimen showed grade 2 ductal carcinoma in situ. No adjuvant radiotherapy was administered due to the history of mantle field radiation. Initially, physicians and patient agreed to frequent radiological screening instead of a completing mastectomy. However, after several additional diagnostic procedures due to suspect lesions of the left breast, in 2001, the patient chose to undergo a SSM and immediate implant reconstruction. In 2003, this was followed by a prophylactic SSM of the right breast and bilateral implant reconstruction. In both cases, histologic investigation showed no (in situ) malignancy.

In 2011, she returned with an ulcerous lesion in the right mastectomy scar. On CT-scan a superficial tumor of 21×27 mm² was seen (Figure 1A). Ultrasonography of the axilla did not show pathological lymph nodes. A wide local excision with axillary lymph node dissection was performed and the implants were removed. Histological examination of the excised specimen showed an invasive ductal carcinoma with a diameter of 2.4 cm, Bloom Richardson grade 3, estrogen receptor (ER) positive, progesterone receptor (PR) and human epithelial growth factor-2 receptor (HER2 receptor) negative (Figure 1B). Adjacent to the tumor, normal glandular breast tissue was found. One out of eight dissected axillary nodes showed a metastasis. According to our national protocol, she received adjuvant chemotherapy, hormonal therapy and re-irradiation with hyperthermia of the chest wall. At the time of writing the patient is alive without breast cancer recurrence.

**Surgical techniques of conservative mastectomies: SSM and NSM**

Examples of conservative mastectomies include SSM and NSM. In SSM, a periareolar incision is used with caudal or lateral extension if necessary (“racquet” incision). The skin envelope is created by subcutaneously excising the breast glandular tissue while preserving a thin subcutaneous layer to support skin vascularization. Nipple-papilla and surrounding pigmented areola (NAC) are removed. In NSM, the skin envelope is created through a semicircular periareolar or an inframammary incision. The NAC is dissected as thin as possible by macroscopically removing all breast glandular tissue while preserving vascularization. The nipple-papilla is “cored” by inverting it and excising residual breast glandular tissue. The NAC is then left in situ adherent to the skin envelope. A breast reconstruction is performed during the same procedure. The oncological safety of SSM in the prophylactic setting is generally acknowledged, whereas safety of NSM is still subject to debate.

In the last two decades of the past century it was
common to perform a so-called subcutaneous mastectomy. Although subcutaneous mastectomy encompassed a skin- and nipple-sparing technique as well, it is likely that this was not comparable to current NSM and SSM techniques. A description of the ‘state of the art’ subcutaneous mastectomy in 1983 mentions that a plaque of one centimeter of breast glandular tissue should be left in situ with the areola (12). In contrast, current NSM and SSM techniques aim for skin flaps <5 mm and NACs of 2-3 mm thickness (13).

**Breast glandular tissue or terminal duct lobular units (TDLUs): residuals after mastectomy**

The hazard of remaining breast glandular tissue after mastectomy for development or recurrence of breast cancer has been a recurring subject to debate since more than half of a century. Anatomically the NAC is a continuation of the mammary gland and therefore should be removed when pursuing a complete mastectomy. Therefore, especially sparing of nipple and areola in NSM has been a controversial topic. However, the growing ability of more specifically identifying women at high breast cancer risk and the consequently increasing interest in prophylactic mastectomies has revived the discussion. Breast cancer is thought to originate in TDLUs, defined as a terminal duct combined with an associated lobule (14-16). Consequently, theoretically any remaining TDLUs may represent a lifelong potential breast cancer hazard. To estimate the remaining risk after prophylactic mastectomy, some authors have studied whether TDLUs are left in situ. Several others have simply examined the presence of remaining ductal or lobular structures or more non-specifically the presence of glandular tissue.

**Residual breast glandular tissue after total mastectomies**

The first study to investigate the amount of glandular tissue left in situ after a conventional total mastectomy was already in 1940 by Hicken et al. (17). The authors had been triggered by two cases of women who developed breast cancer and mastitis of residual axillary breast tissue 15 and 10 years, respectively, after an ipsilateral mastectomy for a benign indication. Mammographies of 385 breasts using intraductal contrast showed that mammary ducts frequently extend beyond regular mastectomy resection planes. In 95%, mammary ducts extended into the axillary fossa, in 15% downward into the epigastric region, in 2% beyond the lateral limits of the latissimus dorsi muscle and in two cases even past the midsternal line to the contralateral side (17). A histological analysis of 17 total mastectomies was performed in the same study by preoperatively injecting methylene blue dye into the ducts of the nipple-papilla. Any resection plane that colored blue during surgery meant that ducts had been cut and the resection site was defined as ‘irradical’ (17). Results showed that breast glandular tissue had been excised irradically underneath the skin flap in 94% of cases, in 12% the axillary tail had been removed irradically, in 23% the ducts had been cut in the sternal region and in 11% in the epigastric region (17). The authors therefore concluded that, even when it is intended to perform a total mastectomy, it is seldom accomplished (17).

In 1991, a small study was performed in ten total mastectomies in five women (18). Frozen sections of skin flaps, pectoral muscle and axillary tail were examined. Similar to the results of Hicken, residual breast glandular tissue was found in caudal skin flaps, the axillary tail and even in the pectoral fascia (18). Another small study separately resected specimens specifically of the inframammary fold (IMF) and encountered small amounts of residual breast tissue in 13/24 IMF specimens (with breast glandular tissue volume/IMF specimen volume rates of 0.04%) (19).

In 2013, Griepsma et al. studied the superficial dissection planes of 206–mostly total–mastectomy specimens (20). Per mastectomy 36 biopsies were obtained from standardized locations of the subcutaneously dissected part of the total mastectomy specimens. In 76% of mastectomies, one or more biopsies contained breast glandular tissue at the resection plane. Areas of predilection were the lower outer quadrant (15% positive biopsies) and halfway the subcutaneous dissection plane between the peripheral pectoral muscle margin and central skin margin (12% positive biopsies) (20).

**Residual breast glandular tissue after conservative mastectomy: SSM and NSM**

Three decades after the first report on total mastectomies by Hicken et al., Goldman and Goldwyn picked up on the issue of conservative prophylactic mastectomy by performing 12 subcutaneous (skin- and nipple-sparing) mastectomies in six cadavers through an inframammary incision (21). Biopsies of post-mastectomy skin flaps, resection planes and any fibrous or adipose tissue remaining elsewhere showed residual breast glandular tissue after 83% of mastectomies (21). In all cases even, residual breast glandular tissue was
found behind the spared NAC. However, the authors do not describe which biopsy sites were positive for breast glandular tissue, nor the surgical technique used for dissection of the NAC (21).

Aiming to investigate the potential value of NSM in the treatment of lobular carcinoma in situ (LCIS), Rosen and Tench (22) vertically sectioned 101 nipples in conventional mastectomies performed for breast cancer. In 17% of the nipples lobules were found and in 13% (in situ) carcinoma was encountered. The authors propose that “coring” of the nipple-papilla in NSM, which had been described before (23), is necessary to remove as much glandular tissue as possible. The NAC was further examined in 1993 (24). By inverting the projected center of the NAC—the nipple-papilla—and grossly removing all glandular tissue inside the papilla, the nipple was cored. Despite nipple-coring the authors did encounter mammary ducts in the areolar dermis (24).

In 1991, Barton et al. compared 27 conservative mastectomies with 28 modified radical mastectomies (25). Post-mastectomy biopsies were taken at the inframammary fold, parasternal region, infraclavicular chest wall, latissimus dorsi muscle border, anterior lower axilla and skin flaps. The NAC was not examined. No differences were found between the number of biopsies containing residual breast glandular tissue after conservative mastectomy (22%) and after total mastectomy (21%) (25). After conservative mastectomy, most positive biopsies (50%) originated in the skin flap. In contrary, after total mastectomy, most positive biopsies (38%) originated at the latissimus dorsi border (25).

The skin flap after conservative mastectomy was further examined in 1998 (26). The authors removed 114 small (0.5x2.0 cm²) strips of skin from the remaining skin flap in 32 patients for complete histological examination. In none of the strips ductal breast tissue was encountered (26), however, regarding the size of the strips, this negative finding may be due to a sampling error. Somewhat larger skin flaps have been examined in a more recent study (27). In 66 SSMs, skin specimens that had been removed additionally to the SSM specimen to facilitate reconstruction were examined for residual glandular tissue. Skin specimens had a mean volume of 93.9 cm³ and in specimens of only four patients (6%) residual breast tissue was found (27). However, since only a minimum of three sites per skin specimen was analyzed, again in this study a sampling error cannot be ruled out. A study of 168 SSMs for therapeutic indication analyzed the superficial margin to the dermis just above the tumor that would have been left in situ otherwise. In contrast with the two studies described above, in 89 (53%) of the cases benign breast ducts were present in the superficial margin specimen (28).

### Residual TDLUs after conservative mastectomy: SSM and NSM

Several studies have more specifically studied whether TDLUs remain after SSM or NSM (22,29-31). The only study on SSM was by Torresan et al. in 2005 (32). In 42 total mastectomies, they resected the skin flap that would have been left in situ if it were a SSM and submitted 80 slides per skin specimen for examination. In contrary to the two studies mentioned earlier, they found TDLUs in 60% of the skin flaps (32). The risk of finding TDLUs strongly increased for skin flaps thicker than 5 mm (32).

The other five studies focus on NSM. Stolier et al. examined the nipple-papilla for presence of TDLUs in 2008 (29). During mastectomies, 32 nipple-papillae were transected at the junction of papilla and areola. Nipple-papillae’s were sectioned, entirely embedded and examined microscopically for presence of TDLUs. Only in three out of 32 nipple-papilla TDLUs were found. Therefore, it was concluded that TDLUs are scarce in the nipple-papilla (29).

Reynolds et al. collected 62 mastectomy specimens from 33 BRCA1/2 mutation carriers and excised the NAC for histologic evaluation (30). In 24% of the NACs, TDLUs were found; only 8% was located in the papilla (30). Similarly, Kryvenko et al. studied 105 NACs from mastectomy specimens (31). Sixty-five NACs were entirely embedded for examination of presence of TDLUs; of 40 NACs only one vertical section was examined. TDLUs were found in 26% of NACs but most frequently were located in the papilla (31)—in contrast to the results of Reynolds and Stolier (29,30). It has been suggested that an areola-sparing mastectomy rather than a NAC-sparing mastectomy should be performed for risk reduction. Removing the nipple-papilla might further reduce any remaining breast cancer risk. However, this is not supported by the abovementioned studies since two of the three show a higher incidence of TDLUs in the areola versus the nipple-papilla.

Recently, our own group compared presence and numbers of TDLUs between skin flap and NAC (33). In 105 total mastectomies, the NAC and an adjacent skin-island were dissected as if an NSM was performed, and the papilla was cored. TDLUs were found in 61% of the NACs vs. 24% of the skin islands (33). Also after adjustment for volume of the excised specimens, density of TDLUs was significantly higher in the NACs as compared with the skin. Further, risk factors for presence of TDLUs were
younger age and parity (vs. nulliparity) (33). We concluded that NACs, as well as skin flaps might harbor a risk for developing breast cancer, albeit very small.

**Oncological safety of prophylactic mastectomy: clinical studies**

In addition to the histopathological studies, we assessed whether there are any oncological consequences of the residual glandular tissue. We performed a systematic PubMed search using the term “prophylactic mastectomy [Title/Abstract] OR skin-sparing mastectomy [Title/Abstract] OR nipple-sparing mastectomy [Title/Abstract] OR subcutaneous mastectomy [Title/Abstract] OR conservative mastectomy [Title/Abstract] OR risk-reducing mastectomy [Title/Abstract] AND breast cancer [Title/Abstract]”, yielding 680 titles. Titles and abstracts were checked for relevance. Reviews and case reports were excluded, as were articles that were not in English. Also excluded were: studies that focused: (I) on merely therapeutic mastectomy and/or comprised <20 prophylactic mastectomies and/or did not report clinical follow-up outcome of prophylactic mastectomies; (II) on survival benefits of contralateral prophylactic mastectomy or oophorectomy; (III) on uptake, counseling and decision-making of prophylactic surgery.

Twenty-four studies from 1976-2014 met our criteria and are summarized in Table 1. All are observational studies describing prospective or retrospective cohorts or a case-control series. In 24 studies, 7,173 mastectomies are described of which 1,392 were for therapeutic indications and which were not considered in further analysis. Most prophylactic mastectomies were performed in BRCA1/2 gene mutation carriers and other women at high breast cancer risk. Average follow-up periods range from 10.4-168 months. Most recent studies focus on NSM rather than SSM; while in older studies conservative mastectomies are defined as ‘subcutaneous mastectomy’, suggesting that the NAC is–partly–spared. However, as described above, it is likely that in subcutaneous mastectomy the NAC and skin are not dissected as thin as modern NSM or SSM techniques dictate.

As reported by the 24 studies in Table 1, grossly, 21 primary breast cancers occurred after 6,044 prophylactic mastectomies. Of these, three occurred after a total mastectomy (0.6% of all total mastectomies), 17 occurred after a conservative mastectomy (0.3% of all subcutaneous mastectomies, NSM or SSM) and for one breast cancer the prophylactic mastectomy technique was not specified. Besides, four patients presented with distant metastases with unknown primary site. Most prophylactic mastectomies included in these studies, as well as the ones in which a primary breast cancer developed, were subcutaneous mastectomies, NSM or SSM. Nonetheless, the majority of primary breast cancers did not originate near the NAC or skin flap. Of the 21 breast cancers that developed after prophylactic mastectomy, five were encountered at the chest wall, four in the axilla, (two in the axillary tail, one in an axillary lymph node, one in an unknown location), one in the outer quadrant, one in the nipple and one “above the areola” (not further specified). In nine cases the location was unclear or not reported.

The 21 loco-regional primary breast cancers correspond with an incidence of 0.7% per woman who undergoes bilateral prophylactic mastectomy (0.35% per mastectomy). Most breast cancers that developed after conservative mastectomy were found at the chest wall or in the axilla. Although the chest wall and the axilla may be at risk in total mastectomy as well, two things should be considered: First, the origin of the breast cancer may have been the skin flap, even though it was described as ‘chest wall’. Most breast implants in immediate breast reconstruction are placed underneath the pectoral muscle. Consequently, skin-flap and chest wall are in direct contact. Therefore, although we have no information on the reconstruction techniques used in these studies, it is possible that the breast cancers developing at the chest wall actually did originate in the skin flap. Second, as mentioned before, the surgical technique of SSM and NSM using small peri-areolar or inframammary incisions can be challenging. A suboptimal exposure may impede thorough removal of remaining breast glandular tissue in all quadrants and in the axillary tail.

In four cases, breast cancer presented as metastatic disease and the primary tumor site was never found. Pathological findings specific for breast cancers, the high a priori breast cancer risk of the patient and elimination of other potential first sites because of negative radiological examinations may all have led to the conclusion that the metastatic disease most probably originated from breast cancer. The possibility that the primary tumor already may have been present in the prophylactic mastectomy specimen emphasizes the importance of standardized pathological examination of the excised specimen, and—even more—through radiological screening by MRI before prophylactic mastectomy.

In conclusion, the incidence of primary breast cancers
Table 1: Primary breast cancers after prophylactic total mastectomy, nipple-sparing and skin-sparing mastectomies: an overview of studies (6-9,13,34-52)

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Study population</th>
<th>Mas</th>
<th>Therapeutic mastectomy not taken into account</th>
<th>Prophylactic mastectomy (PM)</th>
<th>Follow-up after PM</th>
<th>Primary BC after PM</th>
<th>Distant metastases after PM</th>
<th>Location primary breast cancer after PM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>n</td>
<td>Conservative PM SSM</td>
<td>Prophylactic SSM NSM</td>
<td>Total PM</td>
<td>n</td>
<td>Months (range)</td>
<td>n (% of all PM)</td>
</tr>
<tr>
<td>de Alcântara Filho, 2011</td>
<td>125 unknown; 36 BRCA1/2+; 39 non-BRCA1/2; 94 non-BRCA1/2 or unknown</td>
<td>353</td>
<td>157</td>
<td>196</td>
<td>10.4 (5-109)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Arner, 2011</td>
<td>129 BRCA1/2+; 94 non-BRCA1/2 or unknown</td>
<td>446</td>
<td>100</td>
<td>338</td>
<td>79.2 (25.2-168.0)</td>
<td>0</td>
<td>1 metastatic disease 9 yrs after PM (0.2%)</td>
<td>Distant metastases</td>
</tr>
<tr>
<td>Colwell, 2014</td>
<td>285 patients</td>
<td>482</td>
<td>222</td>
<td>260</td>
<td>26.0 (10.8-71.0)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Contant, 2002</td>
<td>63 BRCA1+; 13 BRCA2+; 36 non-BRCA1/2 or unknown</td>
<td>207</td>
<td>193</td>
<td>14</td>
<td>35.0 (12.0-70.8)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Evans, 2009</td>
<td>202 BRCA1/2+; 38 non-BRCA1/2&lt;25% BC risk</td>
<td>864</td>
<td>—</td>
<td>346</td>
<td>73.2 (range NR)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Garcia-Etienne, 2009</td>
<td>25 patients</td>
<td>42</td>
<td>7</td>
<td>34</td>
<td>10.5 (6.4-56.4)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Hagcn, 2014</td>
<td>267 BRCA1/2+; 104 history of BC</td>
<td>449</td>
<td>168</td>
<td>49</td>
<td>35 (2-336)</td>
<td>1 primary BC 6.6 yrs after subcutaneous PM (0.2%)</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Hamans, 2011</td>
<td>6 BRCA1/2+; 37 non-BRCA1/2 or unknown</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>18.5 (8-62)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Hartmann, 1999 and 2001</td>
<td>26 BRCA1/2+; 150 non-BRCA1/2 high risk; 38 not tested; 425 moderate risk</td>
<td>1,278</td>
<td>—</td>
<td>1,146</td>
<td>168 (range NR)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Heamskerk-Gerritsen, 2013</td>
<td>156 BRCA1+; 56 BRCA2+</td>
<td>424</td>
<td>—</td>
<td>384</td>
<td>75.6 (12-208.8)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Jensen, 2010</td>
<td>99 patients</td>
<td>149</td>
<td>99</td>
<td>50</td>
<td>60.2 (12-144)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Kaas, 2010</td>
<td>179 BRCA1+; 75 BRCA2+</td>
<td>401</td>
<td>—</td>
<td>NR (Majority)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>1 primary BC 2 yrs after PM (history of contralateral BC) (0.2%)</td>
</tr>
<tr>
<td>Meijers-Heijboer, 2001</td>
<td>64 BRCA1+; 12 BRCA2+</td>
<td>152</td>
<td>—</td>
<td>148</td>
<td>33.6 (1.2-68.4)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Munhoz, 2013</td>
<td>158 patients genetic status unknown</td>
<td>233</td>
<td>114</td>
<td>119</td>
<td>66.6 (8-130)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Pelae, 2014</td>
<td>53 BRCA1/2+; 53 non-BRCA1/2</td>
<td>212</td>
<td>108</td>
<td>104</td>
<td>51 (8.3-132.8)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>de la Peña-Salcedo, 2011</td>
<td>52 patients</td>
<td>64</td>
<td>—</td>
<td>42</td>
<td>144 (range NR)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Perrini, 1976</td>
<td>1244 patients</td>
<td>64</td>
<td>1,180</td>
<td>84</td>
<td>38 (range NR)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Rebeckeb, 2004</td>
<td>105 BRCA1/2+</td>
<td>210</td>
<td>—</td>
<td>58</td>
<td>66 (6-373)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Sacchini, 2006</td>
<td>3 BRCA1/2+; 1 non-BRCA1/2; 119 unknown</td>
<td>219</td>
<td>68</td>
<td>151</td>
<td>24.6 (2-570.4)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Sikglyt, 2011</td>
<td>67 BRCA1+; 29 BRCA2+</td>
<td>192</td>
<td>—</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>47.3 (range NR)</td>
<td>0</td>
</tr>
<tr>
<td>Speir, 2011</td>
<td>22 BRCA1/2+; 79 non-BRCA1/2 or unknown</td>
<td>162</td>
<td>49</td>
<td>113</td>
<td>43 (5-246)</td>
<td>0</td>
<td>1 metastatic disease of unknown primary after 9 yrs (0.3%)</td>
<td>0</td>
</tr>
<tr>
<td>Wagner, 2012</td>
<td>7 BRCA1/2+; 3 BRCA1/2&lt;; 23 unknown; 33 patients</td>
<td>54</td>
<td>17</td>
<td>37</td>
<td>15.0 (1-29)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Warren Peled, 2012</td>
<td>19 BRCA1/2+; 411 non-BRCA1/2 or unknown</td>
<td>657</td>
<td>412</td>
<td>245</td>
<td>28</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Wilijayapagham, 2008</td>
<td>43 patients; partly BRCA1/2+</td>
<td>76</td>
<td>35</td>
<td>29</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Total numbers of primary BC after conservative and total PM: 472 cases, 151 of which were BRCA1/2+; 141 of which were BRCA1+. The sample size for the study was not reported.

© Gland Surgery. All rights reserved.

www.glandsurgery.org


1. 202 of 338 NSM concerned SSM with retransplantation of the nipple but removal of the areola; 1. women with unilateral and bilateral mastectomies; exact numbers of mastectomies not reported and are analyzed as one mastectomy per woman; 2. conservative mastectomy = subcutaneous mastectomy; 3. of 26 patients (52 mastectomies) mastectomy techniques were unknown. Abbreviations: BC, breast cancer; Mas, mastectomies; PM, prophylactic mastectomy; SSM, skin-sparing mastectomy; NSM, nipple-sparing mastectomy; NR, not reported; N/A, not applicable; BRCA1/2+, female BRCA1/2 gene mutation carrier; BCT, breast conserving therapy.
after prophylactic mastectomy is very low after total as well as after conservative mastectomies. However, theoretically, according to these data, approximately one out of 140 women undergoing bilateral prophylactic mastectomy for breast cancer prevention will develop a primary breast cancer over time. Oncological surgeons should be aware of this risk and may minimize it by putting extra care in dissecting all glandular tissue, especially in the axillary tail and chest wall, and by dissecting skin flaps and NAC as thin as possible. More studies are warranted that further assess long-term oncological safety. Further, it is important to more specifically study patient satisfaction after NSM and SSM and potential differences in patient expectations. Ultimately, surgeons and patients may be able to balance any remaining oncological risk against expected benefits of NSM or SSM.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

45. Munhoz AM, Aldrighi CM, Montag E, et al. Clinical


